预约演示
更新于：2026-07-15
Cyclosporine
环孢素
更新于：2026-07-15
概要
基本信息
权益机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1983-11-14), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构/序列
分子式C62H111N11O12 |
InChIKeyPMATZTZNYRCHOR-CGLBZJNRSA-N |
CAS号59865-13-3 |
Sequence Code 13844772
关联
1,091
项与 环孢素 相关的临床试验NCT07368595
Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks
NCT07352566
Utilization of a Cutaneous Therapy In Situ Microdevice
NCT06364319
Study on the Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (cGVHD) of the Liver Following Allogeneic Hematopoietic Stem Cell Transplantation.
100 项与 环孢素 相关的临床结果
登录后查看更多信息
100 项与 环孢素 相关的转化医学
登录后查看更多信息
100 项与 环孢素 相关的专利（医药）
登录后查看更多信息
58,913
项与 环孢素 相关的文献（医药）2026-12-31Hematology
Cyclosporine A improves survival in lower-risk hypoplastic myelodysplastic syndromes: a single-center retrospective study from China
Article
作者: Liu, Yumei ; Yang, Liyan ; Fu, Rong ; Shao, Zonghong ; Zhang, Wei ; Jiang, Huijuan ; Wang, Huaquan ; Xing, Limin ; Wei, Yansong ; Li, Lijuan
BACKGROUND:
Hypoplastic myelodysplastic syndrome (hMDS) is an uncommon MDS subtype, accounting for approximately 10-15% of cases, characterized by bone marrow hypocellularity, severe cytopenias, and features of immune dysregulation. Its clinical course overlaps with aplastic anemia, yet optimal management for lower-risk patients remains undefined, particularly in Asian populations.
METHODS:
We retrospectively analyzed 48 patients with lower-risk hMDS (IPSS-R very low/low/intermediate) treated at Tianjin Medical University General Hospital from 2013 to 2021. Patients received cyclosporine A (CsA, n = 16), hypomethylating agents (HMAs, n = 10), low-dose HMAs (LD-HMAs, n = 11), or best supportive care (BSC, n = 11). Responses were assessed by modified IWG criteria, and survival was evaluated by Kaplan-Meier and Cox regression analyses.
RESULTS:
Median age was 61 years (range 16-84), with 60.4% male. Somatic mutations were present in 64.6%, and PNH clones in 29.2%. Six-month overall response rates were 75.0% for CsA, 70.0% for HMAs, 54.5% for LD-HMAs, and 36.4% for BSC (p = 0.220). CsA achieved significantly longer complete remission (median 75 months) and hematologic improvement durations (p < 0.05). Median overall survival (OS)/progression-free survival (PFS) for CsA were 78.0/76.0 months, compared with 17.0/6.8 for HMAs, 31.0/15.0 for LD-HMAs, and 36.0/15.0 for BSC (p < 0.01). HMAs were associated with increased grade 3-4 infections.
CONCLUSION:
CsA provides superior response durability, survival outcomes, and safety compared with other approaches, supporting its use as first-line therapy in lower-risk hMDS. Integration of immune and molecular profiling may refine individualized treatment strategies.
2026-12-31Future Science OA
Continuous spinal anesthesia for TURBT in a morbidly obese patient with EF of 20%: a case report
Article
作者: Akhrass, Mohamad ; Tawbe, Zakaria ; Ghandour, Mohamad ; Nahle, Mustapha
BACKGROUND:
Patients with severely reduced left ventricular function pose major anesthetic challenges. General anesthesia may cause cardiac depression and pulmonary decompensation, while single-shot spinal anesthesia can trigger sudden hypotension. Continuous spinal anesthesia (CSA), however, allows gradual dosing and improved hemodynamic stability in such high-risk patients.
CASE PRESENTATION:
We report a 133-kg man with atrial fibrillation, left bundle branch block, global hypokinesia, ejection fraction (EF) of 20%, and prior pulmonary tuberculosis with lung congestion, who underwent transurethral resection of a bladder tumor (TURBT) under CSA. Using the epidural loss-of-resistance technique at L4-L5, a catheter was advanced to 12 cm (6 cm intrathecal). Incremental doses of 1 mg isobaric bupivacaine were administered every 15 minutes to a total of 5 mg. Noninvasive blood pressure was monitored every minute. Baseline BP was 154/98 mmHg and remained stable at 135/90 mmHg intraoperatively, with a heart rate of 65-75 bpm. Adequate anesthesia was achieved without vasopressor use, and recovery was uneventful (Table 1).
CONCLUSION:
Incremental CSA with isobaric bupivacaine was safely and effectively used in a morbidly obese patient with low EF undergoing TURBT. The technique maintained hemodynamic stability throughout, suggesting CSA as a viable anesthetic option for endoscopic urologic procedures in patients with compromised cardiac function.
2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Comparative effectiveness and safety of phototherapy, cytotoxic agents, and biologics in adults with atopic dermatitis: real-world multicenter cohort data
Article
作者: Jannadi, Raed ; Molla, Amr
BACKGROUND:
Real-world comparative evidence on systemic agents, phototherapy, and biologics for atopic dermatitis (AD) remains limited.
OBJECTIVE:
To compare 24-week effectiveness and safety of methotrexate (MTX), cyclosporine, narrowband ultraviolet B (NB-UVB) phototherapy, upadacitinib, and dupilumab in adults with AD.
METHODS:
In this multicenter retrospective cohort (N = 1000; 200 per monotherapy group) across Saudi Arabia, SCORAD was extracted at baseline and mapped to prespecified weeks 2, 6, 12, and 24. Confounding was addressed using a multinomial propensity score (baseline SCORAD, age, sex, nationality) with overlap weighting; balance was assessed using Max |SMD|. Longitudinal change from baseline (ΔSCORAD) was analyzed using overlap-weighted generalized estimating equations with a treatment-by-time interaction, reporting adjusted marginal mean ΔSCORAD (95% CI).
RESULTS:
Unadjusted 24-week improvement was highest with dupilumab (75.8%) and upadacitinib (74.1%) (p < 0.001). In overlap-weighted models, both were associated with the largest week-24 improvements (ΔSCORAD -27.04 and -26.68). NB-UVB and methotrexate were intermediate, whereas cyclosporine had smaller sustained improvement. Upadacitinib had the highest recorded adverse-event frequency (68.5%), whereas dupilumab had the lowest (9%).
CONCLUSION:
Dupilumab and upadacitinib were associated with larger 24-week SCORAD improvements than conventional systemic therapies and NB-UVB within this stratified analytic cohort. Results are associative and may be affected by residual confounding.
100 项与 环孢素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 角结膜炎 | 加拿大 | 2018-12-24 | |
| 春季角膜结膜炎 | 欧盟 | 2018-07-06 | |
| 春季角膜结膜炎 | 冰岛 | 2018-07-06 | |
| 春季角膜结膜炎 | 列支敦士登 | 2018-07-06 | |
| 春季角膜结膜炎 | 挪威 | 2018-07-06 | |
| 干眼综合征 | 欧盟 | 2015-03-19 | |
| 干眼综合征 | 冰岛 | 2015-03-19 | |
| 干眼综合征 | 列支敦士登 | 2015-03-19 | |
| 干眼综合征 | 挪威 | 2015-03-19 | |
| 角膜炎 | 欧盟 | 2015-03-19 | |
| 角膜炎 | 冰岛 | 2015-03-19 | |
| 角膜炎 | 列支敦士登 | 2015-03-19 | |
| 角膜炎 | 挪威 | 2015-03-19 | |
| 干眼症 | 日本 | 2005-10-11 | |
| 干燥综合征性角膜结膜炎 | 美国 | 2002-12-23 | |
| 眼部炎症 | 美国 | 2002-12-23 | |
| 特应性皮炎 | 日本 | 2000-03-14 | |
| 免疫抑制 | 日本 | 2000-03-14 | |
| 重症肌无力 | 日本 | 2000-03-14 | |
| 葡萄膜炎 | 日本 | 2000-03-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 眼部疾病 | 申请上市 | 加拿大 | 2025-01-01 | |
| 角膜溃疡 | 临床3期 | 美国 | 2025-09-01 | |
| 角膜溃疡 | 临床3期 | 印度 | 2025-09-01 | |
| 真菌性角膜炎 | 临床3期 | 美国 | 2025-09-01 | |
| 真菌性角膜炎 | 临床3期 | 印度 | 2025-09-01 | |
| 肝移植排斥反应 | 临床3期 | 美国 | 2012-10-01 | |
| 肝移植排斥反应 | 临床3期 | 澳大利亚 | 2012-10-01 | |
| 肝移植排斥反应 | 临床3期 | 比利时 | 2012-10-01 | |
| 肝移植排斥反应 | 临床3期 | 加拿大 | 2012-10-01 | |
| 肝移植排斥反应 | 临床3期 | 丹麦 | 2012-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 92 | Intravenous steroids | 築繭餘衊餘鬱餘齋積憲(壓簾構膚蓋鹹襯夢艱窪) = 衊淵糧醖窪蓋鏇構鑰壓 齋蓋醖網膚繭憲夢築艱 (窪鏇鹽糧鹹鹹製醖夢構 ) 更多 | 积极 | 2026-06-11 | ||
临床2期 | 46 | 廠糧醖餘遞憲積鹹築製(襯憲構衊鹹廠醖糧襯衊) = 繭夢選網壓製窪餘遞簾 製醖網範範鹹網製襯糧 (鏇鏇構醖鏇觸觸積遞糧, 齋觸膚範獵醖憲積餘衊 ~ 構糧醖鬱夢夢範齋壓範) 更多 | - | 2026-05-26 | |||
临床2期 | 150 | (Arm I (Mycophenolate Mofetil, Cyclosporine, Sirolimus)) | 鑰蓋選鑰艱壓鹹繭獵憲 = 網簾餘襯繭淵齋衊憲齋 觸構獵繭鏇積醖製夢觸 (夢積製願醖範壓選夢鹽, 鹽醖衊壓艱糧網鬱構憲 ~ 範範構製構製襯顧淵選) 更多 | - | 2026-05-14 | ||
(Arm II (Cyclosporine, Sirolimus, Cyclophosphamide)) | 鑰蓋選鑰艱壓鹹繭獵憲 = 壓糧觸鑰廠積選鹽窪膚 觸構獵繭鏇積醖製夢觸 (夢積製願醖範壓選夢鹽, 觸艱窪齋蓋選鏇顧積憲 ~ 憲遞遞範襯鬱構網選築) 更多 | ||||||
N/A | - | 29 | 鏇繭製鬱鏇壓觸築襯夢(壓衊網遞膚選餘壓築齋) = 壓選獵襯鑰醖鹹簾憲簾 衊齋選餘遞製築選積襯 (獵鏇餘窪選範鑰壓夢積 ) 更多 | 积极 | 2026-05-12 | ||
Cyclosporine (CsA) + Anti-thymocyte globulin (ATG) combination therapy | 鏇繭製鬱鏇壓觸築襯夢(壓衊網遞膚選餘壓築齋) = 鹽窪構構廠糧製齋簾鹽 衊齋選餘遞製築選積襯 (獵鏇餘窪選範鑰壓夢積 ) 更多 | ||||||
N/A | 45 | CSA alone | 遞鹽繭簾製衊壓餘窪淵(淵遞製糧糧夢築築觸構) = 鹽襯艱構觸繭鹹簾糧鑰 遞餘構製淵窪夢構鑰鏇 (淵蓋範繭鹽築製構範鏇 ) 更多 | 积极 | 2026-05-12 | ||
N/A | 40 | (pre-eltrombopag era (before 2018)) | 鹽廠艱齋鑰製鬱鬱製衊(顧艱構壓艱積淵鏇構糧) = 簾壓鏇簾觸繭遞築壓製 窪繭蓋蓋範築積鬱觸醖 (鏇壓遞願鏇衊鹽齋遞鬱 ) | 积极 | 2026-05-12 | ||
(post-eltrombopag era) | 鹽廠艱齋鑰製鬱鬱製衊(顧艱構壓艱積淵鏇構糧) = 願簾構壓窪網鑰積窪餘 窪繭蓋蓋範築積鬱觸醖 (鏇壓遞願鏇衊鹽齋遞鬱 ) | ||||||
N/A | 73 | immunosuppressive therapy | 蓋遞膚積糧壓觸簾膚繭(顧鏇窪願遞醖獵夢鑰襯) = 製簾鏇壓選選夢壓窪選 鹹築構淵艱簾膚廠簾簾 (願構齋壓網鑰願壓壓製 ) 更多 | 积极 | 2026-05-12 | ||
临床2期 | 58 | 餘選窪衊鏇衊淵糧鹹壓(醖範襯蓋築廠繭獵艱窪) = 選獵襯廠鑰糧積壓網鏇 遞壓願積齋鏇構積蓋鬱 (鹽範膚鏇積鹽構願憲獵 ) 更多 | 积极 | 2026-04-29 | |||
餘選窪衊鏇衊淵糧鹹壓(醖範襯蓋築廠繭獵艱窪) = 廠淵構蓋顧鏇壓憲鹹夢 遞壓願積齋鏇構積蓋鬱 (鹽範膚鏇積鹽構願憲獵 ) 更多 | |||||||
N/A | 1,898 | Methotrexate/Cyclosporine | 鏇餘獵觸願繭壓積網餘(窪構夢夢夢獵網憲餘壓): HR = 0.66 (95.0% CI, 0.37 ~ 1.15) 更多 | 积极 | 2026-03-27 | ||
Glucocorticoids | |||||||
N/A | - | 341 | 壓窪餘淵簾選構鹹窪艱(鹹夢夢窪鬱窪齋願積遞) = Adverse events were age-dependent. Hypertension rose with age, peaking at 33% in 70-year-olds (p=0.001). Renal toxicity was highest in ages 55–69 (17%, p=0.002), with creatinine elevation (p<0.001), and GFR reduction (p<0.001) increasing with age. Hyperlipidemia peaked at 14% in ages 35–55 (p=0.031), and infection was most common in patients <35 (13%, p=0.019). 壓鹹艱構艱壓膚鏇齋鑰 (鹽衊製艱製艱醖蓋糧夢 ) 更多 | 不佳 | 2026-03-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用